Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 10 months from now) | |
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 3 months ago) | |
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) | |
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Aug 22, 2023 |
New Patient Population (NPP) | Oct 17, 2025 |
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: TABLET;ORAL
17
United States
9
Japan
6
European Union
5
Norway
5
Australia
4
China
4
Canada
4
New Zealand
3
Spain
3
Hong Kong
3
Denmark
3
Croatia
3
Korea, Republic of
3
Cyprus
3
Portugal
3
Lithuania
3
Slovenia
3
Hungary
2
AP
2
Czech Republic
2
Poland
2
Brazil
2
Ukraine
2
EA
2
Mexico
2
South Africa
1
Uruguay
1
Turkey
1
India
1
Iceland
1
Moldova, Republic of
1
RS
1
Singapore
1
Morocco
1
Estonia
1
Argentina
1
OA
1
ME
1
San Marino
1
Belgium
1
Peru
1
Israel
1
Chile
1
Taiwan
1
Costa Rica
1
Ecuador
1
Bulgaria
1
Netherlands
1
Colombia
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic